Association of oxidative stress and paraoxonase status with PROCAM risk score

Clinical Biochemistry

Volumn 42, Issue 7-8, 2009, Pages 617-623

  Stefanović, Aleksandra ^a   Kotur Stevuljević, Jelena ^a   Spasić, Slavica ^a   Vekic, Jelena ^a   Bujisić, Nada ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinical Chemistry Laboratory Belladonna   (Serbia)

Author keywords

Oxidative stress; Paraoxonase; PROCAM risk score

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; CARDIOVASCULAR RISK; CLASSIFICATION ALGORITHM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL;

ALGORITHMS; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PHENOTYPE; RISK FACTORS; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 63749109644     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.01.008     Document Type: Article

References (41)

1. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol. Med. 28 12 (2000) 1815-1826
2. Maritim A.C., Sanders R.A., and Watkins J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17 1 (2003) 24-38
3. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87 (2000) 840-844
4. Fruchart J., Nierman M.C., Stroes E.S.G., Kastelein J.J.P., and Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 109 (Jun 2004) III-15-III-19
5. Holvoet P., and Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis 137 Suppl (1998) S33-S38
6. Stocker R., and Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
7. Mackness M.I., Abbott C., Arrol S., and Durrington P.N. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294 Pt 3 (1993) 829-834
8. Ruiz J., Blanche H., James R.W., Garin M.C., Vaisse C., Charpentier G., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346 8979 (1995) 869-872
9. Kabaroglu C., Mutaf I., Boydak B., et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol. 59 6 (2004) 606-611
10. Mackness M., Durrington P., and Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr. Opin. Lipidol. 15 4 (2004) 399-404
11. Sanghera D.K., Aston C.E., Saha N., and Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62 1 (1998) 36-44
12. Li H.L., Liu D.P., and Liang C.C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J. Mol. Med. 81 12 (2003) 766-779
13. Assmann G., and Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J. 116 6 Pt 2 (1988) 1713-1724
14. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28 (1979) 1039-1057
15. The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). Final report. Circulation. 2002; 106: 3143-3421.
16. Girotti M.J., Khan N., and Mc Lellan B.A. Early measurement of systemic lipid peroxidation products in plasma of major blunt trauma patients. J. Trauma 31 (1991) 32-35
17. Auclar C., and Voisin E. Nitroblue tetrazolium reduction. In: Greenworld R.A. (Ed). CRC handbook of methods for oxygen radical research (1985), CRC Press, Boca Raton, Fla 123-132
18. Misra H.P., and Fridovich I. Chemistry and metabolism of substances of low molecular weight: the role of superoxide anion in the Autoxidation of Epinephrine and a Simple Assay for Superoxide Dismutase. J. Biol. Chem. 247 (1972) 3170-3175
19. Ellman G.l. Tissue sulfhydryl groups. Arc. Biochem. Biophys. 82 (1952) 70-77
20. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9 6 (1999) 745-753
21. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52 3 (1993) 598-608
22. Serrato M., and Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96 6 (1995) 3005-3008
23. http://www.chd-taskforce.com/.
24. Assmann G., Carmena R., Cullen P., Fruchart J., Jossa F., Lewis B., et al. Coronary heart disease: reducing the risk: a worldwide view. Circulation 100 (1999) 1930-1938
25. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 105 (2002) 310-315
26. Bland J.M., and Altman D.G. Statistics notes: transformations, means and confidence intervals. BMJ 312 (1996) 1079-1080
27. Hosmer D.W., and Lemeshow S. Assessing the fit of the model. Applied logistic regression (2000), John Wiley and sons, NY 160-164
28. Pearson T.A., Mensah G.A., and Alexander R.W. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
29. Madamanchi N.R., Vendrov A., and Runge M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 29-38
30. Cheesman K.H., and Slater T.F. An introduction to free radical biochemistry. Br. Med. Bull. 49 (1993) 481-493
31. Minuz P., Fava C., and Lechi A. Lipid peroxidation, isoprostanes and vascular damage. Pharmacol. Rep. 58 Suppl (2006) 57-68
32. Esterbauer H., Schaur K.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal malondialdehyde and related aldehydes. Free Radic Biol. Med. 11 (1991) 81-128
33. Galan A.I., Palacios E., Ruiz F., et al. Exercise, oxidative stress and risk of cardiovascular disease in the elderly. Protective role of antioxidant functional foods. BioFactors 27 1-4 (2006) 167-183
34. Jung H.H., Choi D.H., and Lee S.H. Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am. J. Nephrol. 24 5 (2004) 537-542
35. Weinbrenner T., Cladellas M., Covas M.I., et al. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 168 1 (2003) 99-106
36. Stephens J.W., Gable D.R., Hurel S.J., Miller G.J., Cooper J.A., and Humphries S.E. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin. Chem. 52 (2006) 446-452
37. Ozdemir G., Ozden M., Maral H., Kuskay S., Cetinalp P., and Tarkun I. Malondialdehyde glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminemia. Ann. Clin. Biochem. 42 (2005) 99-104
38. Mackness M.I., Hallam S.D., Peard T., Warner S., and Walker C.H. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp. Biochem. Physiol. B 82 4 (1985) 675-677
39. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 1-2 (1993) 129-135
40. Bhattacharyya T., Nicholls S.J., Topol E.J., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
41. La Du B.N. Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1317-1318